1 – 10 of 207
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's disease
- Contribution to journal › Article
-
Mark
CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease
- Contribution to journal › Article
-
Mark
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals : implications for clinical trials
- Contribution to journal › Article
-
Mark
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers : a longitudinal cohort study
- Contribution to journal › Article
-
Mark
Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
- Contribution to journal › Article
-
Mark
Complementary utility of plasma biomarkers and Aβ-PET for diagnosis, risk-stratification, and treatment monitoring in Alzheimer's disease
- Contribution to journal › Debate/Note/Editorial
-
Mark
Locus coeruleus-entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein
- Contribution to journal › Article
-
Mark
Plasma p-tau217 correlates strongly with cerebrospinal fluid Aβ42 and increases over a ten-year period in amyloid-positive, non-demented very old men
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum
- Contribution to journal › Article
-
Mark
Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum
- Contribution to journal › Article
